Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Amidate shortage

Executive Summary

Abbott files sNDA requesting approval for use of alternate supplier for Amidate active ingredient etomidate. Company announces shortage of anesthetic in June 18 "Dear Clinician" letter. "Our approved supplier of the active pharmaceutical ingredient has exited the market," letter says. "Clinicians are requested to utilize Amidate judiciously for the interim period of time until Abbott is able to manufacture sufficient inventory to once again meet the market demands." Shortages of another anesthetic, fentanyl, prompted Abbott to double its own production last year (1"The Pink Sheet" March 21, 2001, p. 16)...

You may also be interested in...



Abbott Doubles Fentanyl Production To Address Hospital Shortages

Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel